Candriam S.C.A. Lowers Stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)

Candriam S.C.A. reduced its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) by 13.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 253,965 shares of the company’s stock after selling 40,659 shares during the period. Candriam S.C.A. owned approximately 0.27% of Edgewise Therapeutics worth $6,781,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of EWTX. Braidwell LP purchased a new position in Edgewise Therapeutics during the 3rd quarter worth $52,267,000. Janus Henderson Group PLC boosted its holdings in Edgewise Therapeutics by 74.8% during the third quarter. Janus Henderson Group PLC now owns 4,558,519 shares of the company’s stock worth $121,616,000 after buying an additional 1,951,220 shares in the last quarter. Walleye Capital LLC purchased a new stake in Edgewise Therapeutics during the third quarter worth about $6,466,000. Ally Bridge Group NY LLC acquired a new position in Edgewise Therapeutics during the third quarter worth about $5,010,000. Finally, JPMorgan Chase & Co. raised its position in Edgewise Therapeutics by 146.3% during the third quarter. JPMorgan Chase & Co. now owns 158,506 shares of the company’s stock worth $4,231,000 after acquiring an additional 94,147 shares during the last quarter.

Insider Transactions at Edgewise Therapeutics

In other news, insider Marc Semigran sold 29,709 shares of the stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $29.69, for a total value of $882,060.21. Following the completion of the sale, the insider now directly owns 6,716 shares of the company’s stock, valued at $199,398.04. This represents a 81.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin Koch sold 8,636 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $30.03, for a total transaction of $259,339.08. Following the transaction, the chief executive officer now directly owns 14,478 shares in the company, valued at approximately $434,774.34. The trade was a 37.36 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 164,545 shares of company stock valued at $4,605,305 over the last three months. 24.11% of the stock is owned by corporate insiders.

Edgewise Therapeutics Trading Down 0.4 %

NASDAQ:EWTX opened at $28.01 on Friday. Edgewise Therapeutics, Inc. has a twelve month low of $14.90 and a twelve month high of $38.12. The company has a 50-day moving average of $26.78 and a 200-day moving average of $27.76. The firm has a market cap of $2.67 billion, a price-to-earnings ratio of -18.67 and a beta of 0.22.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its earnings results on Monday, March 3rd. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.03). On average, research analysts forecast that Edgewise Therapeutics, Inc. will post -1.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on EWTX shares. Stifel Nicolaus assumed coverage on shares of Edgewise Therapeutics in a research report on Wednesday, January 22nd. They issued a “hold” rating and a $30.00 price objective for the company. Royal Bank of Canada reiterated an “outperform” rating and set a $56.00 price objective on shares of Edgewise Therapeutics in a research note on Tuesday. Wedbush boosted their price objective on shares of Edgewise Therapeutics from $44.00 to $45.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Scotiabank began coverage on shares of Edgewise Therapeutics in a research note on Friday. They issued a “sector outperform” rating and a $50.00 target price for the company. Finally, Evercore ISI upped their price target on shares of Edgewise Therapeutics from $45.00 to $50.00 and gave the company an “outperform” rating in a report on Tuesday, December 17th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $45.38.

Edgewise Therapeutics Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.